Evidence map›Paper›PMID 41756348›Full record

ArticleToxicology reports2026

Evaluation of the safety of high-dose

Hajime Fuchida, Daisuke Sawada, Tatsuhiko Hirota, Hiroki Miyashita, Kazuhiko Takano, Koji Mochizuki

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Toxicology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hajime FuchidaAsahi Quality and Innovations Ltd., Department of Group Project Strategy, Moriya 302-0106, Japan.
Daisuke SawadaAsahi Quality and Innovations, Ltd., Core Technology Laboratories, Moriya 302-0106, Japan.
Tatsuhiko HirotaAsahi Quality and Innovations, Ltd., Core Technology Laboratories, Moriya 302-0106, Japan.
Hiroki MiyashitaClinical Support Corporation, Clinical Trial Division Sapporo Branch, Hokkaido, Sapporo 060-0061, Japan.
Kazuhiko TakanoMedical Corporation Hokubukai Utsukushigaoka Hospital, Hokkaido, Sapporo 004-0839, Japan.
Koji MochizukiAsahi Quality and Innovations Ltd., Department of Group Project Strategy, Moriya 302-0106, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Methods: Among 95 participants who provided written informed consent, 44 who met the eligibility criteria were randomly assigned to either the Results: One participant was excluded from the analysis; thus, the final analysis included data from 22 participants in the Conclusion: The results of this study demonstrate that no safety concerns were identified in the physical examinations, hematology, blood biochemistry, urinalysis, or subjective symptoms. These findings support the safety of

Indexed as

High-DoseL. gasseri CP2305Safety

Identifiers

PMID41756348
PMCPMC12933801

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.